Signature



Downloaded on 11/11/2011



Athena Endocrinology Test Requisition (October 2011)

*Indicates required information

Medicare Patients - Please use the Athena Diagnostics Endocrinology Medicare Test Requisition Form.

For a copy, please call Client Services or visit our website: www.AthenaDiagnostics.com/medicare.

Medicaid/Patients Without Insurance - Please complete the patient identification information, and we will contact the patient directly.

PATIENT

Commercially Insured Patient Information

Complete this requisition for all patients with commercial insurance. Patients with a commercial insurance plan for which Athena is a contracted provider are subject to any co-insurance and deductible of their plan. Patients with a commercial insurance plan for which Athena is not a co-insurance plan for which Athena is not a contracted provider but who have diagnostic testing (including genetic testing where applicable) as a defined benefit on their insurance plan may, in certain States, participate in Athena's Patient Protection Plan. Under this plan, the patient's out-of-pocket exposure will be no more than 20% of billed charges or \$500, whichever is less. Athena will bill the patient's insurance for the total price of the test and work on his or her behalf to file all appropriate justifications and/or appeals to maximize the amount paid by the insurance when applicable. Upon receipt of the patient specimen, Athena will contact the patient to gather any missing insurance information and explain the Patient Protection Plan. if the patient does not choose to participate in the Patient Protection Plan, Athena will still bill their insurance company. However, if the insurance company does not pay the full amount, the patient may be responsible for the balance.

1. Commercial insurance does not include certain Medicare, Medicare HMO, Medicare PPO, Medicaid, or Tricare/Champus programs for which there is a specific government-mandated billing process. Patients should verify coverage with their individual provider prior to testing.
2. Due to State laws, the Patient Protection Plan is not available in all States

Patient Identification

Deticut Names

First	Last
Patient ID # (if available)	
S.S. #	Sex: ☐ Male
DOB*	Female
Age*	Unknown
Mailing Address*	
City*	State* Zip*
Phone #1*	Day Eve Cell
	🗆 Day 🗆 Eve 🗆 Cell
authorize Athena Diagnostics or their designee, to actions and information necessary to overturn th	payment or denial by my insurance carrier, I hereby appeal my health plan on my behalf ³ to provide the e denial or receive reimbursement for the underpaid he charges for the orders on this form are paid in full.
insurance carrier all information, including test re that if I choose not to participate in the Patient F not covered by my insurance carrier within sixty that benefits under this claim be paid directly to within thirty (30) days any payment for these se charges for the test(s) ordered by my physician in the control of the patient of	Benefits: I authorize Athena Diagnostics to provide my sults, concerning my laboratory test(s). I understand frotection Plan* I may be responsible for all charges (60) days of claim submission. I authorize and direct Athena Diagnostics, and I agree to remit to Athena rvices made directly to me. I acknowledge that the will be withdrawn in the event of cancellation only if physician and a copy of the written confirmation or to the issuance of the test result.
Due to State laws, the Patient Protection Plan is not average perform this appeal on my behalf, but is not obligated.	ailable in all States. 3. Athena Diagnostics and or designee ated to do so.
Patient Signature*	
Date	
Patient Insurance Information	
	front and back of the insurance card.
Name of Insured*First	Last
	☐ Parent ☐ Spouse ☐ Other
Member ID #*	
Group ID #*	
Insurance Co. Name*	
Address*	
City*	State* Zip*
Phone	•

Type of Specimen ☐ Whole Blood

Physician/Laboratory Contact Information

NOTE: Specimen tube(s) must be labeled with two of the following forms of identification: name, date of birth, social security no., patient ID no. These same two forms of ID should also be indicated on the test requisition.

PHYSICIAN

Contact Name	First		Last
Phone		Fax	
Email			
Tests Ordered Important: Wr	-	e and test name	(see list on reverse).
Code	_ Name		
Code	_ Name		
ICD-9 Cd	ode (Required): _		
Required Phy	ysician Informa	tion	
NPI #*		UPIN :	# *
Name*	First	Last	
City		State	Zip
Phone*		_ Fax	
Email*			
Additional A	uthorized Resu	It Report Reci	pient
Name	First	Last	
	.IA #		
Address	(P.O. Box	x not acceptable)	
			Zip
Phone		_ Fax	·
Email			

Indications for Testing (Check One)*

☐ Diagnostic (symptomatic)	☐ Clinical Study	☐ Prenatal
☐ Predictive (asymptomatic)	☐ Carrier	☐ Other Research

Warrant of Informed Consent

Testing Authorization: I warrant that this test was ordered and is either: 1) for the purpose of diagnosing or detecting an existing disease, illness, impairment, symptom or disorder, or 2) that if it is not for such purpose, I have obtained the appropriate prior written consent. This written consent was signed by the person who is the subject of the test (or if that person lacks capacity to consent, signed by the person authorized to consent for that person), and includes: a) a statement of the purpose and description of the test; b) a statement that prior to signing the consent form, the consenting person discussed with the medical practitioner ordering the test the reliability of positive or negative test results and the level of certainty that a positive test result for that disease or condition serves as a predictor of such disease; c) a statement that the consenting person was informed about the availability and importance of further testing, physician consultation and genetic counseling, and provided with written information identifying a genetic counselor or medical geneticist from whom the consenting person might obtain such counselling; d) a general description of each specific disease or condition tested for; and e) the person or persons to whom the test results may be disclosed as indicated above.

Medical Practitioner Signature*


NOTE: Specimen tube(s) must be labeled with two of the following forms of identification: name, date of birth, social security no., patient ID no. These same two forms of ID should also be indicated on the test requisition.

Date Collected*

For Athena's Specimen Collection Service*, Please Fax this Test Requisition to Access Athena™ at 866-223-1247

☐ Serum

*Specimen collection service will work with the patient to obtain phlebotomy services through either a home draw or other laboratory. See online catalog at AthenaDiagnostics.com for complete specifications and shipping information.





Athena Endocrinology Test Requisition (October 2011)

Tests included in multi-test evaluations may be ordered individually.



Test Code	Test Name	Genes Included	Test Code	Test Name		Genes Included
Adrena	al Disorders		NOTE:	Athena is a mer	mber of the International Standard	Cytogenomic Array Consortium
□ 816	Primary Adrenal Insufficiency				identified, HIPAA-compliant genomi	
	(Addison's disease)	ABCD1, NR0B1, AIRE			tion (NCBI) database. The NCBI is a rves the mission of advancing our u	
	☐ 815 ABCD1 DNA Sequencing Test (X-lin	ked Adrenoleukodystrophy)			ves the mission of advancing our t	
	☐ 814 NR0B1/DAX1 DNA Sequencing Tes			enital Hyperinsı		<u>.g . 000 00 </u>
	(X-linked Adrenal Hypoplasia Cong	· · · · · · · · · · · · · · · · · · ·	□ 819	Ongenital Hy	yperinsulinism Evaluation	
	☐ 881 Endocrine Hypertension (HSD11B2 (Apparent Mineralocorticoid Excess) DNA Sequencing Test		GLUD1, GCK, I	KCNJ11, ABCC8	
	□ 855 PHEX DNA Sequencing Test	2)			Study (check one or more below):	
	(X-linked Hypophosphatemic Ricke	ets)			de Responsive	
	☐ 856 FGF23 DNA Sequencing Test (Auto				de Non-Responsive	
	Dominant Hypophosphatemic Rick	ets)	.	☐ Hypogly		
□ 879	Congenital Adrenal Hyperplasia Evaluatio			•	or Gestational Age (LGA)	
	CYP21A2 sequencing and deletion, CYP11E	<u> </u>	.	Other (c	·	
	☐ 880 CYP21A2 (CAH) DNA Sequencing a				O1 (CH) DNA Sequencing Test	
	Required: Indication for Study (che	ck one or more below):			(CH) DNA Sequencing Test J11 (CH) DNA Sequencing Test	
	☐ Virilization (ambiguous genitalia				C8 (CH) DNA Sequencing Test	
	☐ Salt Wasting	a)	□ 04°		Testing – To augment child/proba	nd diagnosis
	☐ Parent/sibling of CAH patient		042		d diagnosis of proband, send pare	-
	• •	HP) elevated concentration in serum			provide information below.	mur tooting dampied do doon d
	☐ Other	in your action and in cordin		☐ Mother ☐	☐ Father	
	☐ 875 CYP11B1 (CAH) DNA Sequencing T	est		Proband Name	e/Accession #	
□ 874	Lipoid CAH (STAR) DNA Sequencing Test		Diabe	tes		
	CYP17A1 DNA Sequencing Test		Antibo	dy Tests with P	Reflex to MODY 1, 2, 3	
□ 878	HSD3B2 DNA Sequencing Test		Spe	cimen Requirer	nents: 1 mL serum drawn in a ser	rum separator or red top
□ 881	Endocrine Hypertension (HSD11B2) DNA Se	quencing Test			AND 10 ml. whole blood drawn	in a lavender top (EDTA) tube
Bone D	Diseases			□ 806 GAD.	-65 with Negative Reflex to MODY 1	• • •
□ 860	Osteogenesis Imperfecta Evaluation	COL1A1, COL1A2			with Negative Reflex to MODY 1, 2,	
	☐ 861 COL1A1 (OI) DNA Sequencing Test				vith Negative Reflex to MODY 1, 2, 3	
	☐ 862 COL1A2 (OI) DNA Sequencing Test		.		ude if patient has received exogeno	
	Osteoporosis-Pseudoglioma (LRP5) DNA Sec				etes Antibody Panel with Negativ	
	Idiopathic Osteoporosis (LRP5) DNA Sequen		·		1. GAD65, IA-2, and IAA; Step 2. I	MODY 1, 2, and 3
□ 857	Hypophosphatemic Rickets Evaluation	PHEX, FGF23	.	dy Tests Only		
	☐ 855 PHEX (Hypophosphatemic Rickets)☐ 856 FGF23 (Hypophosphatemic Rickets		Spe		nents: 1 mL serum drawn in a seri	um separator or red top
Chrom	nosome Microarray Analysis	b) DNA Sequencing Test	:	□ 820 GAD-	-65	
	180K WholeGenome Chromosomal Micro	array Analysis*	'	□ 838 IA-2 □ 896 IAA		
	60K WholeGenome Chromosomal Microa				ude if patient has received exogeno	us insulin)
Whole	Genome Microarray Specimen Requiremen	t:		•	etes Antibody Panel	,
10	mL whole blood drawn in a lavender top tube	(EDTA)		GAD	65, IA-2, and IAA	
40	AND		□ 850		Diabetes (MODY) Evaluation	
	mL whole blood drawn in a green top tube diatric minimum: 4 mL in each tube				formed in this order: K, HNF4A, HNF1B sequencing and o	Holotian IDE1 coguancing
	diatile infillinatil. 4 the fit each tube dication for Study (MUST check one or mor	e halow):		2. CEL seque		deletion, if it sequenting
mu	- · · · · · · · · · · · · · · · · · · ·	Moderate □ Severe			4A (MODY1) DNA Sequencing and D	eletion Test
		Moderate ☐ Severe			(MODY2) DNA Sequencing and Dele	
	☐ Autistic Spectrum	☐ Failure to Thrive		□ 804 HNF1	1A (MODY3) DNA Sequencing and D	eletion Test
	☐ Multiple Congenital Anomalies	☐ Infertility		□ 834 IPF1	(MODY4) DNA Sequencing Test	
	☐ Trisomy 13 ☐ Trisomy 18	☐ Trisomy 21		□ 805 HNF1	1B (MODY5) DNA Sequencing and D	eletion Test
	☐ Dysmorphic Features			□ 837 CEL	(MODY8) DNA Sequencing Test	
	☐ Fetal Demise ☐ Seizures ☐ Multiple Miscarriages (#)	☐ Klinefelter Syndrome☐ Testicular Failure	□ 882	Neonatal Dial	betes Mellitus Evaluation	IPF1, GCK, KCNJ11, INS, ABCC8
	☐ Turner Syndrome	☐ Ambiguous Genitalia		□ 841 IPF1	(NDM) DNA Sequencing Test	
				□ 842 GCK	(NDM) DNA Sequencing Test	
	☐ Family History:			□ 843 KCN.	J11 (NDM) DNA Sequencing Test	
Previou	s Cytogenetic Results (if applicable):				NDM) DNA Sequencing Test	
ramily I	Members Studied by Athena:			□ 876 ABC0	C8 (NDM) DNA Sequencing Test	
Probano	d Accession #:					

Code	Test Name	Genes Included	Code	Test Nan	me	Genes Included
Nephro	ogenic Diabetes		Obesity	,		
□ 854	Nephrogenic Diabetes	AVPR2, AQP2	□ 884	Early Ons	set Obesity Panel	LEPR, MC4R
	Insipidus Evaluation			□ 883	Early Onset Obesity (LEPR) DNA Sequencing	g Test
	□ 851 Nephrogenic Diabetes Insipidus (AVPR2)			□ 640	Early Onset Obesity (MC4R) DNA Sequencing	ng Test
	DNA Sequencing Test		□ 887	Bardet-B	Biedl Syndrome Evaluation	BBS1, BBS2, BBS10
	☐ 852 Nephrogenic Diabetes Insipidus (AQP2) DNA Sequencing Test				BBS1 (BBS) DNA Sequencing Test	
Familia	al Cancer Syndromes				BBS2 (BBS) DNA Sequencing Test	
□ 818	MEN1 (MEN1) DNA Sequencing Test				BBS10 (BBS) DNA Sequencing Test	
□ 889	Pheochromocytoma Evaluation	RET, VHL, SDHB		uctive Dis		
	☐ 813 MEN2 (RET) DNA Sequencing Test				cocious Puberty (LHCGR) DNA Sequencing	Test
	□ 858 von Hippel-Lindau Syndrome (VHL)		Short S			
	DNA Sequencing Test		□ 865		d Pituitary Hormone cy Evaluation	PROP1, POU1F1
	☐ 888 SDHB DNA Sequencing Test				PROP1 (CPHD) DNA Sequencing Test	
Familia	al Hypocalciuric Hypercalcemia				POU1F1 (CPHD) DNA Sequencing Test	
□ 829	amilial Hypocalciuric Hypercalcemia (CASR)				Syndrome (PTPN11) DNA Sequencing Test	
	DNA Sequencing Test				, , , ,	OUT OUDUD
	al Testing – Targeted Analysis		□ 848	Growth H	Hormone Deficiency (GHD) Evaluation	GH1 and GHRHR seq.; SHOX seg. and del.
□ 800 Familial DNA Sequence Evaluation				□ 866	GH1 (GHD) DNA Sequencing Test	
This test detects previously identified sequence variants in at-risk family members. This test is available for HNF4A, GCK, TCF1, IPF1, TCF2, COL1A1, COL1A2,				GHRHR (GHD) DNA Sequencing Test		
	MEN1, and RET mutations	,		SHOX (GHD) DNA Sequencing and Deletion	Test	
	Proband Accession # Relationsl	nip	□ 867		DNA Sequencing Test	
Lipid D	lisorders					
□ 895	Hypercholesterolemia Evaluation	LDLR, APOB			under exclusive license from Correlagen Dia	ignostics, Inc.,
	☐ 894 LDLR (Hypercholesterolemia) DNA Sequen	cing Test	www.co	rrelagen.co	om	
	☐ 893 APOB Mutation Analysis					
The follo	wing tests are sendouts to Quest Diagnostics Nichols Insti	tute: GAD-65, IA-2, and IAA.				

Specimen Requirements* & Shipping Information (applies to all tests)

Specimen Type: Whole blood, 10 mL in yellow or lavender top (pediatric minimum volume: 2 mL)

Stability: Hemolysis may compromise DNA recovery and integrity after 48 hrs. Store for short periods only (until shipped) at 4°C.

Shipping: Send specimen overnight at room temperature (must arrive less than 24 hrs after collection). Ship Monday through Thursday only.

*Please Note: As indicated in the test listing, Diabetes Antibody Tests with Reflex to MODY 1, 2, 3 (Test Codes 806, 807, 808, 809) and Diabetes Antibody Tests Only (Test Codes 820, 838, 896, 897) have differing specimen requirements from those indicated above.

NOTE: Specimen tube(s) must be labeled with two of the following forms of identification: name, date of birth, social security no., patient ID no. These same two forms of ID should also be indicated on the test requisition.

Billing Information

Insurance Billing/Patient Protection Plan: Patients with a commercial insurance plan¹ for which Athena is a contracted provider are subject to the deductible and co-insurance obligations of their plan. For these patients, Athena will bill insurance directly for all of our services and there will be no up-front charges paid to Athena by the patient. Athena will forward the appropriate notification of obligation to the patient as specified by the Explanation of Benefits (EOB). In all instances, Athena will adhere to the terms of the patient's individual policy insofar as payments for services are concerned. Patients should check with their local provider for pre-authorization and coverage questions related to our services.

Patients with a commercial insurance plan for which Athena is a contracted provider are subject to any co-insurance and deductible of their plan¹. Patients with a commercial insurance plan for which Athena is not a contracted provider but who have diagnostic testing (including genetic testing where applicable) as a defined benefit on their insurance plan may, in certain States,² participate in Athena's Patient Protection Plan. Under this plan, the patient's out-of-pocket exposure will be no more than 20% of billed charges or \$500, whichever is less. Athena will bill the patient's insurance for the total price of the test and work on his or her behalf to file all appropriate justifications and/or appeals to maximize the amount paid by the insurance when applicable. Upon receipt of the patient specimen, Athena will contact the patient to gather any missing insurance information and explain the Patient Protection Plan. If the patient does not choose to participate in the Patient Protection Plan, Athena will still bill their insurance company. However, if the insurance company does not pay the full amount, the patient may be responsible for the balance.

1. Commercial insurance does not include certain Medicare, Medicare HMO, Medicare PPO, Medicaid, or Tricare/Champus, programs for which there is a specific government-mandated billing process. Patients should verify coverage with their individual provider prior to testing. 2. Due to State laws, the Patient Protection Plan is not available in all States.



Athena Diagnostics Client Service Representatives are available from 8:30 a.m. to 6:30 p.m. Eastern Time (US).

Customers in the US and Canada please call toll-free

866-AthenaDx (866-284-3623)

(Non-US customers please call 508-756-2886 or fax 508-753-5601.)

Four Biotech Park, 377 Plantation Street Worcester, MA 01605 • AthenaDiagnostics.com

